NYSE:ASHChemicals
Ashland (ASH) Is Down 7.7% After Tightening 2026 Outlook And Detailing New Cost Savings Targets
Ashland recently reported past growth in its Life Sciences revenue and adjusted EBITDA, narrowed its FY2026 adjusted EBITDA outlook to US$400 million–US$420 million, and outlined roughly US$30 million of expected FY2026 savings from a broader US$90 million manufacturing optimization program.
Despite headwinds from a facility outage and asbestos litigation reserves, Ashland emphasized a strong balance sheet and plans for double-digit-plus adjusted EPS growth, underscoring how cost initiatives...